drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
CD19-directed CAR-engineered natural killer (NK) cellular immunotherapy; adoptive transfer of CAR+ NK cells to target CD19-positive B-cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Engineered natural killer cells expressing an anti-CD19 chimeric antigen receptor are adoptively transferred to recognize CD19 on malignant B cells and induce targeted cytotoxicity (perforin/granzyme release and cytokine-mediated killing). Lymphodepleting preconditioning (e.g., fludarabine/cyclophosphamide) enhances CAR-NK expansion and persistence.
drug_name
F01
nct_id_drug_ref
NCT06206902